A professional team consisting of a pharmacist, a microbiologist, and an economist dreamed up a unique light therapy product line that uses light to destroy pathogens inside the body without causing harm to human cells. The brand is named Babypurp and is released on the market after medical approval. The patent for the use of the 405-nanometer wavelength light on mucous membranes covers the treatment of 13 bacterial, viral, and fungal infections.
The Babypurp story began with the oral thrush illness of microbiologist László Tálas’s son, which was healed by the fungus-killing effect of light in laboratory conditions. László, who is now the company’s professional leader, began the patent process and teamed up with Noémi Marencsák, who has experience in pharmaceutical marketing, and Gergely Kiss, who has great expertise in clinical research, to create the special pacifier. Noémi entered several startup competitions to validate the concept’s business potential. Her successful participation in the Women Startup Competition organized by pozi.io caught the attention of Design Terminal, and Babypurp was selected as one of the 11 most promising startup teams in its mentor program this spring.
According to the company’s operational leader, although Babypurp looks and functions much like a traditional pacifier, it is actually a medical device. The pacifier’s nipple does not just serve the traditional purpose; it disperses light inside the child’s mouth. The device’s additional advantage is that it can already destroy 70 percent of fungal colonies in the first 30-minute treatment, immediately reducing pain and soothing the baby.
